AstraZeneca welcomes the recommendations by the National Institute for Health and Clinical Excellence (NICE) on the treatment of Familial Hypercholesterolaemia (FH) 1, a genetic condition resulting in high cholesterol levels. As part of its comprehensive review on the identification and management of people with FH, NICE has recommended that adults with the condition be treated with high intensity statins in order to reduce LDL-cholesterol (LDL-C) levels by 50%.